The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (“the Company or “Abliva”) are hereby convened to the Annual General Meeting, held at 1 p.m. on Thursday, 23 May 2024 at Me ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (the “Company”), are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 3 p.m. on Tuesday 26 Ma ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 11.00 a.m. on Wednesday 8 March 2023 at ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 1 p.m. on Friday, 20 May 2022 at Medicon Village, Scheeletorget ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) held at 11.00 a.m. on Friday 14 January 2022 at Medico ...

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.

The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 3 pm on Tuesday 17 March 2020 at Medicon Village, Scheelevägen 2, ...

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 25, 2019, at 4 pm at Medicon Village, Scheelev ...